Sanofi-Aventis Administrative Office
Col. Coyoacan, Mexico
NCT Number: NCT01024192
Primary Objective:
To evaluate the efficacy and safety of the use of Stilnox CR in Mexican patients with chronic insomnia at the prescription conditions of daily practice
Secondary Objective:
To evaluate the satisfaction of the patient with chronic insomnia with Stilnox CR over an as needed basis.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 4
Col. Coyoacan, Mexico
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Moreover, in order to follow the international regulations in terms of the use and handling of hypnotic compounds, and to guarantee the appropriate study performance, no patients with one or more of the following characteristics should be included:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Pharmaceutical form: Zopidem 12.5 mg tablets
Route of administration: Oral
Dose regimen:One tablet at bed time and as needed (the patients choose which night they take the tablet without limit of number of nights)
Time frame: At day 84 (visit 5)
Time frame: At day 1 (baseline), day 14 (visit 2), day 28 (visit 3), day 56 (visit 4) and day 84 (visit 5)
Time frame: At day 1 (baseline), day 28 (visit 3), day 56 (visit 4) and day 84 (visit 5)
Time frame: At day 84 (visit 5)
Time frame: At day 14 (visit 2), day 28 (visit 3), day 56 (visit 4) and day 84 (visit 5)
Sanofi
Industry
Efficacy and Safety Assessment of ZOlpidem (Stilnox CR) Administered on as Needed Basis in Patients With Chronic insomNIA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07708623
Mental Disorders, Nervous System Diseases
Moscow, Russia
View Trial DetailsNCT07695103
Mental Disorders, Nervous System Diseases
Guangzhou, Guangdon, China
View Trial DetailsNCT06755593
Mental Disorders, Mononeuropathies
Qui Nhon, Binh Dinh, Vietnam
View Trial DetailsNCT00071786
Brain Diseases, Central Nervous System Diseases
Bethesda, Maryland, United States
View Trial Details